Advancing Radiotherapeutic Solutions for Rare Cancers
At Plus Therapeutics, our mission is clear: to develop safe, effective, and lasting solutions for patients facing rare and hard-to-treat cancers. Every day, our dedicated team works alongside clinicians and researchers to move the field of radiotherapeutics forward and ultimately improve outcomes for patients with limited treatment options.
We are grateful for the support of the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Cancer Prevention and Research Institute of Texas (CPRIT). Their contributions are helping power our active clinical trials, including:
🔬 ReSPECT-GBM Phase 2 Clinical Trial – Investigating REYOBIQ™ (rhenium Re186 obisbemeda) for patients with recurrent glioblastoma (GBM)
🔬 ReSPECT-LM Phase 1 Clinical Trial – Targeting leptomeningeal metastases (LM) in breast and lung cancer patients
Now Recruiting: ReSPECT-GBM Phase 2 Trial
We are currently enrolling glioblastoma patients for our ongoing Phase 2 clinical trial. If you or someone you know may be eligible, please visit the trial site to learn more:
http://respect-trials.com
At Plus Therapeutics, we believe that precision radiotherapeutics like REYOBIQ™ have the potential to change the standard of care for some of the most challenging cancers.
#ReSPECTGBM #ReSPECTLM #Glioblastoma #GBM #LeptomeningealMetastases #BreastCancer #Radiotherapeutics #OncologyResearch #CancerTreatment #ClinicalTrialRecruitment #RareCancerResearch #NIH #NCI #CPRIT #PlusTherapeutics
Recent Comments